fluticasone propionate + formoterol fumarate + tiotropium bromide

This drug is a fixed-dose combination of three active ingredients used in the management of chronic obstructive pulmonary disease (COPD) and, less commonly, severe asthma. The components are: - Fluticasone propionate, an inhaled corticosteroid that reduces airway inflammation by activating glucocorticoid receptors. - Formoterol fumarate, a long-acting beta2-adrenergic receptor agonist (LABA) that induces bronchodilation by relaxing bronchial smooth muscle through stimulation of beta2-adrenoceptors. - Tiotropium bromide, a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at muscarinic receptors in the airways to prevent bronchoconstriction. Triple therapy with these agents is indicated for patients with COPD who continue to experience symptoms or exacerbations despite dual therapy. This combination targets different pathways involved in airway obstruction and inflammation to improve lung function and reduce exacerbation risk[1][6][8].